Clinical Trial Update: Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing safety, pharmacokinetics and pharmacodynamics of Kamada anti-SARS-CoV-2 therapy in COVID-19 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Kamada anti-SARS-CoV-2 therapy

Snippet

Sponsor: Kamada, Ltd. | Conditions: Covid19, Pneumonia, Viral | Phase 1, Phase 2 | Status: COMPLETED